All In Biotech

Drug Trial Radar · NCT05363722

Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC

A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Mar 6, 2025

Primary completion

Jan 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Shanghai Zhongshan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • IBI310(1mg/kg)Drug

    IBI310 1mg/kg IV d1 Q6W

  • sintilimabDrug

    sintilimab 200 mg IV d1 Q3W

  • bevacizumabDrug

    bevacizumab 15 mg/kg IV d1,Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse Event, TEAETime frame: Any emergent adverse event from first dose through study completion, up to 2 years.
  2. Severe Adverse Event, SAETime frame: Any severe adverse event from first dose through study completion, up to 2 years.
  3. Objective response rate (ORR)Time frame: The proportion of patients with complete response or partial response, through study completion, up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital, Fudan University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.